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Background. Infection with nontuberculous mycobacteria (NTM) is of growing clinical concern in people with cystic fibrosis 
(CF). The epidemiology of infection in children and young people remains poorly understood. Our goal was to investigate the epi-
demiology of NTM infection in the pediatric age group using data from the UK CF Registry.
Methods. Data from 2010–2015 for individuals aged <16  years (23 200 observations from 5333 unique individuals) were 
obtained. Univariate analysis of unique individuals comparing all key clinical factors and health outcomes to NTM status was per-
formed. The significant factors that were identified were used to generate a multivariate logistic regression model that, following 
step-wise removal, generated a final parsimonious model.
Results. The prevalence of individuals with a NTM-positive respiratory culture increased every year from 2010 (45 [1.3%]) to 
2015 (156 [3.8%]). Allergic bronchopulmonary aspergillosis (odds ratio [OR], 2.66; P = 5.0 × 10−8), age (OR, 1.08; P = 3.4 × 10−10), 
and intermittent Pseudomonas aeruginosa infection (OR, 1.51; P = .004) were significantly associated with NTM infection.
Conclusions. NTM infection is of increasing prevalence in the UK pediatric CF population. This study highlights the urgent 
need for work to establish effective treatment and prevention strategies for NTM infection in young people with CF.
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More than 10 000 individuals have cystic fibrosis (CF) in the 
United Kingdom, making it the most common inherited 
life-limiting condition [1]. More than 4000 are aged <16 years 
[1]. The CF Trust maintains a detailed UK patient registry that 
records anonymized clinical data and health outcomes [2]. The 
registry is updated annually and captures information that cov-
ers more than 90% of people with CF nationally [1, 2]. Despite 
the development of specialist care and incremental improve-
ments in survival, lung disease still accounts for the substantial 
majority of morbidity and premature mortality in people with 
CF [3]. Susceptibility to respiratory infection with particular 
microbes is a key component of the pathology of CF lung dis-
ease, and approaches that target the treatment or prevention of 
infection are a mainstay of clinical management [3].
Over the last 5 years, infection with nontuberculous myco-
bacteria (NTM) has become a subject of increasing clinical 
concern in people with CF [4]. NTM are environmental organ-
isms found commonly in soil and water. Two groupings are most 
frequently isolated from people with CF, Mycobacterium absces-
sus complex and Mycobacterium avium complex. Infection with 
M. abscessus specifically has been found to be associated with 
increased decline in lung function [5, 6]. Treatment of airway 
infection with NTM requires prolonged courses of multiple 
antibiotics, often for more than 12  months, and is associated 
with a significant treatment burden and frequent adverse effects 
[4, 7]. Furthermore, M. abscessus infection is regarded as a rel-
ative contraindication to lung transplantation in many centers 
[8]. There is also emerging evidence to suggest transmission of 
M. abscessus between individuals with CF [9, 10].
There are varying estimates of the prevalence of NTM isola-
tion in respiratory samples from people with CF that range from 
3.7% in parts of Europe to 14% in the United States [11, 12]. 
Several reports have suggested an increasing prevalence over 
the last decade above that accounted for by improved screen-
ing and detection techniques [5, 13–16]. A previous European 
registry study of a combined adult and pediatric CF popula-
tion identified age; allergic bronchopulmonary aspergillosis 
(ABPA); Stenotrophomonas maltophilia infection; and use of 
bronchodilators, inhaled antibiotics, or rhDNase to be associ-
ated with NTM infection [17]. Specific knowledge of the epide-
miology of NTM infection in children and young people with 
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CF is particularly limited at present. Paradoxically it is in the 
pediatric age group where interventions and strategies to treat 
or prevent infection with NTM are likely to yield the greatest 
clinical benefits.
We analyzed data from the UK CF Registry to investigate the 
epidemiology of NTM infection in individuals aged <16 years 
between 2010 and 2015. This included trends in the prevalence 
of NTM infection, individual species isolated, demographic 
and clinical “risk factors” in individuals isolating NTM, along 
with longitudinal analyses. These data and analyses will inform 
future clinical research relating to NTM infection in children 
and young people with CF.
METHODS
Clinical Data and Research Ethics
Annual review data submitted to the UK CF Registry data-
base between 2010 and 2015 for patients aged <16 years (23 200 
observations from 5333 unique individuals) were obtained. 
Supplementary Table 1 lists the variables obtained. Data lacking a 
unique identifying code were excluded from the analysis (n = 38).
Explicit written consent is obtained from individuals or their 
parents or guardians for their inclusion in the UK CF Registry. 
The registry is compliant with UK data protection legislation 
and subject to continued Research Ethics Committee approval. 
Data for this study were obtained by application to the CF Trust 
Research Registry Committee, which approved the application 
and released anonymized data in line with the existing registry 
ethics approvals.
Data Analyses
The data were first cleaned and checked for duplicates. For each 
individual, NTM-positive status was defined using the specific 
registry field, which is returned if an individual has had a pos-
itive NTM culture in the preceding year. Intrinsically, this was 
not whether an individual met the criteria for NTM-related 
pulmonary disease (NTM-PD) but purely whether they had a 
positive culture in that 12-month period [18]. In the 2014 and 
2015 registry censuses, this field was expanded to collect more 
detailed data about NTM status, including species, date of cul-
ture, and treatment data. Individuals were tracked through the 
time period using their unique registry ID.
All unique individuals were then pooled for analysis of epide-
miological risk factors predictive of NTM status. These included 
demographics (age, sex, anthropometric measurements), CFTR 
genotype, lung function, other respiratory microbiological 
status (P. aeruginosa, Staphylococcus aureus, and Burkholderia 
cepacia; S.  aureus and P.  aeruginosa were subdivided into 3 
states: negative; intermittent, defined as 1–2 isolations in the last 
year; or chronic, defined as 3 or more isolations in the last year), 
and comorbidities (CF-related diabetes or ABPA).
Following a standard approach, univariate nonparamet-
ric tests were used to assess predictive value. All significant 
predictors were then included in a multivariate logistic regres-
sion model. Step-wise removal of nonsignificant factors was 
then undertaken to generate the final parsimonious model pre-
sented. For variables with multiple categorical states included 
in the multivariate model, for example, P. aeruginosa status, an 
overall effect was estimated using the Wald test.
Next, the progress of patients’ NTM status was tracked over 
the entire time period to generate annual incidence, prevalence, 
and potential response to treatment estimates. For patients who 
remained NTM positive or NTM negative for the duration of 
the study period, only their latest time point was included for 
analysis. Those with multiple classifications, that is, those who 
developed or were cleared of NTM infection during the study 
period, were classified as NTM positive, and data from their lat-
est NTM-positive time point were included for analysis.
Finally, descriptive data on NTM species and treatment were 
collated and explored for the 2014 and 2015 data extracts. All 
analyses were carried out using Microsoft Access 365, GraphPad 
Prism 6.05, and R 3.4.1 using the nlme package [19].
RESULTS
The prevalence of individuals with a NTM-positive respira-
tory culture in the UK CF Registry aged <16  years increased 
every year from 2010 (45 [1.3%]) through 2015 (156 [3.8%]; 
Figure  1). An especially large increase in cases was observed 
between 2013 (83 [2.1%]) and 2014 (140 [3.6%]). Following the 
pooling of yearly cohorts, the number of overall unique NTM 
cases was identified (288 from 5333 [5.4%]).
Table 1 summarizes the differences between those children 
and young people who had an NTM-positive respiratory cul-
ture and those who did not. On average, children who isolated 
NTM were older (median 10 years vs 6 years, P = 2.2 × 10–16), 
were more likely to be positive for P. aeruginosa (45% vs 30%, 
P  =  .013), more likely to be positive for B.  cepacia (2.4% vs 
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Figure  1. Nontuberculous mycobacteria (NTM) prevalence by year. The preva-
lence of NTM in cystic fibrosis patients increased each year, with a particularly 
large increase observed between 2013 and 2014. After merging of the data, the 
number of unique cases overall (288, 5.4%) was identified. Values in brackets show 
percentage of individuals positive for NTM per year.
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy531/5049416
by University of Newcastle user
on 09 August 2018
 • CID 2018:XX (XX XXXX) • 3NTM Infection in Children With CF
0.9%, P =  .013), and more likely to have ABPA (17% vs 4.7%, 
P = 2.2 × 10–16).
No gender difference was seen, nor was there a difference 
between F508del (c.1521 1523del) homozygotes or heterozy-
gotes. Heterozygosity for the W1282X (c.3846G>A) mutation 
was statistically significantly associated with positive NTM sta-
tus. However, given the scarcity of this (21 heterozygotes) and 
other rare mutations in the dataset, the chance of statistical 
error was deemed too great for further analysis.
While, on average, individuals who had a respiratory culture 
positive for NTM had a lower body mass index percentile (44.3 
vs 53.4, P = .850) and lower forced expiratory volume in 1 sec-
ond percentile (81.3 vs 86.4, P = .286), neither was statistically 
significantly different. No difference was seen between rates of 
S.  aureus, Burkholderia cenocepacia, and Burkholderia multiv-
orans infection between the 2 groups. There was no statistically 
significant difference in the incidence of CF-related diabetes 
between the NTM-positive and NTM-negative groups (3.8% vs 
2.8%, P = .321).
Following univariate analysis and step-wise logistic regres-
sion, age, P.  aeruginosa, B.  cepacia, and ABPA status were 
incorporated into a multivariate model (Table 2, Figure 2). In 
the final model, increased age and ABPA were significantly 
associated with NTM status, with a larger effect observed for 
ABPA (age odds ratio [OR], 1.08; 95% confidence interval 
[CI], 1.06–1.11; P = 3.4 × 10−10 and ABPA OR, 2.66; 95% CI, 
1.85–3.75; P  =  5.0 ×  10−8, respectively). Intermittent, but not 
Table 1. Summary of Merged Registry Data for 2010–2015 and Univariate Analysis of Risk Factors for Nontuberculous Mycobacteria–positive Cultures
All NTM NTM Negative
Variable n (%) Median (Quartiles) n (%) Median (Quartiles) n (%) Median (Quartiles) P  Value
Patients 5333 (100) … 288 (5.4) … 5045 (94.6) … …
Demographics
Male 2717 (50.9) … 138 (47.9) … 2579 (51.1) … .554
Female 2615 (49) … 150 (52.1) … 2465 (48.9) …
Age, years 5333 (100) 6 (2–12) 288 (100) 10 (7–12) 5045 (100) 6 (2–12) 2.2 × 10−16
Height percentile 5110 (95.8) 112.2 (79.6–142.6) 282 (97.9) 133.9 (117.7–145.9) 4828 (95.7) 110 (78.7–142) .020
Weight percentile 5235 (98.2) 19.3 (10.9–34.9) 281 (97.6) 28.8 (21.5–37.6) 4954 (98.2) 18.6 (10.6–34.7) .420
Body mass index percentile 3846 (72.1) 52.8 (28.2–76.1) 262 (91) 44.3 (22.1–70.48) 3224 (63.9) 53.48 (28.5–76.53) .850
Genotype
F508del F508del 2704 (50.7) … 164 (56.9) … 2540 (50.3) … .418
F508del/Other 1968 (36.9) … 89 (30.9) … 1879 (37.2. … .452
Other/Other 661 (12.4) … 35 (12.2) … 626 (12.4) … .469
Lung function
FEV1 2541 (47.6) 1.64 (1.2–2.2) 64 (22.2) 1.5 (1.2–1.9) 2728 (54.1) 1.7 (1.2–2.2) .991
FEV1% predicted 2271 (42.6) 85.9 (73.4–97.5) 76 (26.4) 81.3 (68.2–94.1) 2986 (59.2) 86.4 (74.3–97.8) .286
Respiratory microbiology
Staphylococcus aureus 1298 (24.3) … 85 (29.5) … 1213 (24) … …
 Chronic 319 (6) … 23 (8) … 296 (5.9) … .093
 Intermittent 979 (18.4) … 62 (21.5) … 917 (18.2) … .103
Pseudomonas aeruginosa 1640 (30.8) … 130 (45.1) … 1510 (29.9) … .013a
 Chronic 505 (9.5) … 45 (15.6) … 460 (9.1) … 8.65 × 10−06
 Intermittent 1135 (21.3) … 85 (29.5) … 1050 (20.8) … 1.93 × 10−05
Burkholderia cepacia 54 (1) … 7 (2.4) … 47 (0.9) … .013
Burkholderia cenocepacia 13 (0.2) … 2 (0.7) … 11 (0.2) … .111
Burkholderia multivorans 25 (0.5) … 3 (1) … 22 (0.4) … .143
Comorbidities
Allergic bronchopulmonary 
aspergillosis
285 (5.3) … 49 (17) … 236 (4.7) … 2.2 × 10−16
Cystic fibrosis–related diabetes 153 (2.9) … 11 (3.8) … 142 (2.8) … .321
Summary statistics for merged data. Thirty-eight data points lacking a unique identifying code were removed from the analysis, leaving a final count of 5333 patients. Univariate analysis 
comparing each factor to NTM status was performed and P values presented. Significant factors (in bold) were included in the final multivariate analysis. 
Abbreviations: FEV1, forced expiratory volume exhaled at the end of the first second of forced expiration; NTM, nontuberculous mycobacteria.
aBy Wald test, χ2 = 8.6, P = .013. Tested prior to inclusion in multivariate model.
Table 2. Odds Ratios and Significance for Multivariate Model
Variable
Odds 
Ratio
95% Confidence 
Interval P  Value
Allergic bronchopulmonary 
aspergillosis
2.656 1.854–3.748 5.0 × 10-8
Pseudomonas aeruginosa  
intermittent
1.511 1.139–1.990 .004
P. aeruginosa chronic 1.275 0.875–1.825 .195
Age 1.084 1.057–1.111 3.4 × 10-10
Odds ratios, 95% confidence interval, and P values for allergic bronchopulmonary aspergillo-
sis, chronic and intermittent P. aeruginosa, and age from the multivariate model are displayed. 
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chronic, P. aeruginosa colonization was also significantly asso-
ciated (OR, 1.51; 95% CI, 1.14–1.99; P = .004). B. cepacia was 
not significantly associated and hence removed from the final 
parsimonious model.
By following individual patients through the registry longitu-
dinally, it was possible to determine the incidence of new cases 
as a proportion. Between 2011 and 2013, approximately 40% 
(approximately 26 cases per year) of NTM-positive individu-
als were new cases (Table 3, Figure 3A). As discussed above, a 
large increase in the overall number of NTM cases was observed 
between 2013 and 2014, which was accounted for by a large 
increase in the number of new cases arising that year (63% [88]).
We then assessed the outcomes for patients who did not car-
ryover NTM-positive status into the following year’s analysis 
based on the registry data. Between 2010 and 2012, approxi-
mately 2 (approximately 4%) patients per year cleared NTM for 
the duration of the study (Table 4, Figure 3B). In 2013 and 2014, 
there was a marked increase in this number up to 16 (19.3%) 
and 33 patients (23.6%), respectively. However, it is likely that 
some of this effect is due to the endpoint of existing data.
From 2014 the registry began including NTM typing infor-
mation from patient isolates and treatment information where 
available. For both 2014 and 2015, M.  abscessus (72 [51.4%] 
and 55 [35.3%], respectively) and M.  avium (16 [11.4%] and 
13 [8.3%], respectively) accounted for the majority of known 
infections (Figure 4, Supplementary Table 2). A  large propor-
tion of samples lacked specific typing information in 2014 (46 
[32.9%]), which increased in 2015 (86 [55.1%]).
A wide variety of therapies were used in the treatment of 
NTM. Descriptive data are presented in Supplementary Table 3 
on the different antimicrobials used. Treatments broadly fol-
lowed accepted guidelines, with amikacin preferentially used 
for the treatment of M. abscessus over M. avium [4, 7]. In a small 
number of cases, ethambutol and rifampicin are recorded as 
having been used to treat M. abscessus, which is not in keeping 
with guidance and is likely to have been ineffective.
DISCUSSION
We present data from the nationally representative UK CF 
Registry that show an increase in children and young people 
isolating NTM in respiratory cultures between 2010 and 2015. 
Over a 5-year period, there was a 3-fold increase in the preva-
lence of NTM-positive cultures, with approximately 5% of those 
aged <16 years included in the registry being NTM positive at 
some point during the study period. M. abscessus complex and 
M. avium complex accounted for the overwhelming majority of 
isolates. Similar to other cohorts, age and ABPA status appeared 
ABPA
Intermittent P. aeruginosa
Chronic P. aeruginosa
Age
0.5 1 5
Odds Ratio
Figure  2. Odds ratios (ORs) for multivariate model. ORs and 95% confidence 
interval for allergic bronchopulmonary aspergillosis, chronic and intermittent 
Pseudomonas aeruginosa, and age from the multivariate model are displayed. 
Values are shown in Table  2. Abbreviation: ABPA, allergic bronchopulmonary 
aspergillosis.
Table 3. Nontuberculous Mycobacteria Origin
Year New Cases (%) Carryover (%) Reinfection (%) Total
2010 45 (100) 0 (0) 0 (0) 45
2011 26 (41.9) 36 (58.1) 0 (0) 62
2012 26 (38.2) 41 (60.3) 1 (1.5) 68
2013 27 (32.5) 54 (65.1) 2 (2.4) 83
2014 88 (62.9) 45 (32.1) 7 (5.0) 140
2015 76 (48.7) 76 (48.7) 4 (2.6) 156
Total (%) 288 (52.0) 252 (45.5) 14 (2.5) 554
Origin of nontuberculous mycobacteria cases per year, data visualized in Figure 3A.
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Figure 3. Nontuberculous mycobacteria (NTM) origin and patient outcomes. A, 
Individual patients were tracked through the registry, and the source of infection 
was graphed. Large increases in the total number and percentage of new cases 
were observed between 2013 and 2014. Values are shown in Table 3. B, Patient out-
comes for those who did not carryover NTM-positive status into the following years 
analysis were also determined. A large increase in those who cleared NTM for the 
remainder of the assessment period was observed for 2013 and 2014. Values are 
shown in Table 4. “Lost to registry” refers to patients who should have remained 
available for analysis but lacked registry data for later years for unknown reasons. 
“Lost to analysis” refers to patients who became older than 16 years and so were 
no longer included in the analysis.
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to be significant predictors of NTM culture positivity, in addi-
tion to P. aeruginosa status [17].
A major strength of this study is derived from the nationally 
representative longitudinal source data. The UK CF Registry 
is an internationally recognized resource, with more than 90% 
of individuals with CF in the United Kingdom included in the 
dataset. The methodology of data collection has remained con-
sistent over the time period we report, meaning that we can 
have confidence that reporting bias should not be a factor in 
these estimates. Second, this dataset  allows investigation and 
analysis of the epidemiology of NTM infection specifically in 
individuals aged <16 years and represents the largest pediatric 
cohort analyzed in this regard. There are important biological 
differences as CF lung disease progresses through a spectrum 
from the early stages in children to advanced disease in adults. 
Furthermore, children and young people receive care in pediat-
ric centers that may adopt models of care that are different from 
those used in adult centers.
Conversely, the limitations of our study stem from the fun-
damental structure, as we had no direct control over reporting, 
and are inherent to registry-based research. The registry does 
not record data on the frequency of sampling in patients or the 
sample types used. However, all UK centers delivering care are 
expected to adhere to the 2010 CF Trust guideline, Laboratory 
Standards for Processing Microbiological Samples from People 
with Cystic Fibrosis. Furthermore, the Standards for the Clinical 
Care of Children and Adults with Cystic Fibrosis in the UK, pub-
lished in 2011, states that all patients should have a respiratory 
sample cultured for NTM at least annually. It is possible, how-
ever, that surveillance on only a yearly basis may lead to under-
estimation of the true prevalence. In some cases, there was no 
recording of the individual species of NTM in the registry.
It is also important to state that the presence of positive respi-
ratory cultures for NTM is not synonymous with NTM-PD as 
defined by the American Thoracic Society/Infectious Diseases 
Society of America 2007 statement [18]. The diagnosis of 
NTM-PD requires multiple clinical criteria to be met and is 
beyond the scope of this study.
The question of whether the increase in prevalence of NTM 
represents a true rise in NTM-PD in UK children with CF or 
simply represents better detection is a vexatious one. Similar 
questions have arisen in virtually every epidemiological study 
of infection, and the data we present cannot fundamentally dif-
ferentiate between these 2 possibilities. Methods to culture and 
detect NTM in respiratory samples have developed over recent 
years. For example, a new selective NTM growth medium has 
been demonstrated to increase sensitivity of the detection of 
NTM, but this is used in a minority of UK CF centers [14, 20, 
21]. Over the same time period, reports have suggested pos-
sible transmission of NTM, specifically M. abscessus complex, 
between individuals with CF despite the presence of routine 
infection control measures in CF centers, which would provide 
a potential mechanism for the observed increasing prevalence 
[9, 10, 22, 23].
Within our cohort, we found associations with increasing age 
(OR, 1.08; P = 3.4 × 10−10), ABPA (OR, 2.66; P = 5.0 × 10−8), 
and P. aeruginosa status (intermittent OR, 1.51; P =  .004) and 
risk of NTM-positive respiratory samples. These were consist-
ent findings over the different annual cohorts and were also 
M. abscessus + Unknown
M. abscessus + M. chelonae
M. abscessus + M. avium M. abscessus
M. avium
M. kansasii
Unknown
2014 2015
Figure 4. Specific strain information for 2014–2015. For 2014–2015, the regis-
try introduced nontuberculous mycobacteria typing information. Some variation 
between years was observed, especially in relation to the number of unknown 
cases. Mycobacterium abscessus and Mycobacterium avium accounted for the 
majority of cases for each year. Values are shown in Supplementary Table 2.
Table 4. Nontuberculous Mycobacteria Patient Outcomes
Year Lost to Analysis (%) Cleared for Duration (%) Later Reinfection (%) Lost to Registry (%) Total
2010 6 (13.3) 1 (2.2) 2 (4.4) 0 (0) 9
2011 12 (19.4) 3 (4.8) 6 (9.7) 0 (0) 21
2012 9 (13.2) 3 (4.4) 2 (2.9) 0 (0) 14
2013 17 (20.5) 16 (19.3) 4 (4.8) 1 (1.2) 38
2014 26 (18.6) 33 (23.6) 0 (0) 5 (3.6) 64
Total 70 56 14 6
Nontuberculous mycobacteria patient outcomes per year, data visualized in Figure 3B.
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found in the pooled analysis of all unique individuals. Viviani 
et al reported similar associations with age and ABPA, but not 
P. aeruginosa, in multivariate analysis of European registry data 
from both children and adults with CF combined [17].
It is conceivable that all 3 identified risk factors in our study 
represent surrogate markers of increased lung destruction or 
damage that has been postulated to increase an individual’s vul-
nerability to NTM acquisition in individuals without CF [24, 25]. 
Advancing age is also associated with an inherent increase in 
duration of time at risk of exposure. There may also be ecologi-
cal interactions within the lung microbiome that predispose to 
coacquisition of P.  aeruginosa, Aspergillus species, and NTM. 
Furthermore, host immune function is likely to be relevant to 
these risk factors. In people with chronic obstructive pulmo-
nary disease, the use of inhaled corticosteroids has been found 
to be a risk factor for NTM infection [26]. ABPA is usually 
treated with corticosteroids, and it is conceivable that there is a 
similar association in people with CF.
Our finding of a difference in the association between NTM 
status and intermittent and chronic P. aeruginosa status is coun-
terintuitive. The distribution of the CIs of the chronic status 
(Figure  2), however, strongly favors an effect, and the overall 
class effect (combining both chronic and intermittent status) is 
significant. We suspect that this difference would likely disappear 
in larger populations. It is worth noting that the UK CF Registry 
classification of P. aeruginosa status is based on the number of 
positive respiratory samples during the last 12 months (nega-
tive; intermittent, defined as 1–2 isolations; or chronic, defined 
as 3 or greater isolations), irrespective of whether or not the 
individual is maintained on chronic antipseudomonal suppres-
sion therapy, for example, nebulized antibiotics.
Our results highlight that NTM infection appears to be 
increasing significantly in the UK pediatric CF population. An 
observation made anecdotally and expressed readily at CF cli-
nician meetings over the last 5 years. These data make a com-
pelling argument for urgent investment in research of NTM 
infection in children and young people. The advances we have 
seen in clinical outcomes in CF have largely come from inno-
vations and improvements in pediatric CF care. Similarly, by 
addressing NTM infection in childhood, the greatest potential 
gains can be made. Our data lead us to conclude that 2 areas in 
particular need urgent focus and collaboration. First, precise, 
detailed epidemiological data on NTM infection in childhood 
need to be obtained so that strategies to prevent acquisition 
can be developed. Second, urgent randomized trials of anti-
microbial therapies directed against M. abscessus complex and 
M. avium complex in children and young people are required.
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